Novartis suspends production of radioligand therapies due to potential quality issues
Novartis temporarily suspended production at two of its radioligand therapy production sites.Novartis took the voluntary action “out of an abundance of caution as a result of potential quality issues” identified in the manufacturing process, a company-issued press release stated.